search
Back to results

DoVe Trial: Dorsal Onlay Versus Ventral Onlay in Isolated Bulbar Urethral Strictures (DoVe)

Primary Purpose

Urethra Stenosis

Status
Recruiting
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Free graft urethroplasty
Sponsored by
University Hospital, Ghent
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Urethra Stenosis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Voluntarily signed written informed consent according to the rules of Good Clinical Practice (Declaration of Helsinki) and national regulations (Appendix B).
  • Age ≥ 18 years.
  • Male patient.
  • Fit for operation, based on the surgeon's expert opinion.
  • Isolated bulbar urethral stricture confirmed by imaging.
  • Preputium, penile shaft skin, buccal mucosa and lingual mucosa are allowed as free graft material in the executed dorsal onlay or ventral onlay FGU.
  • Patient is able and willing to attend the follow-up consultations.

Exclusion Criteria:

  • Absence of signed written informed consent (Appendix B).
  • Age < 18 years.
  • Female patients.
  • Transgender patients.
  • Patients unfit for operation.
  • Concomitant urethral strictures at other urethral locations (penile urethra, membranous urethra, prostatic urethra, bladder neck).
  • A unique urethral stricture at other urethral locations (penile urethra, membranous urethra, prostatic urethra, bladder neck).
  • Prior bulbar urethroplasty.
  • Lichen Sclerosus related strictures.
  • Strictures after failed hypospadias repair.
  • Patients with neurogenic bladder.
  • History of pelvic radiation therapy.
  • Shift of technique to any other technique than dorsal or ventral onlay FGU due to any circumstance (post-hoc exclusion).
  • Utilization of free graft material other than preputium, penile shaft skin, buccal mucosa or lingual mucosa.
  • Any condition or situation, which, in the investigator's opinion, puts the patient at significant risk, could confound the study results, or may interfere significantly with the patient's participation in the study.
  • Patient declares that it will be impossible for him to attend the follow-up consultations.

Sites / Locations

  • Ghent University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Dorsal onlay graft urethroplasty

Ventral onlay graft urethroplasty

Arm Description

Outcomes

Primary Outcome Measures

Failure-free survival after 24 months
Failure is defined as the inability to pass a flexible 16 Fr cystoscope through the reconstructed area without damaging the urethral mucosa.

Secondary Outcome Measures

Change in postoperative erectile function
Assessed with IIEF 5 questionnaire (international index on erectile function: score between 5 and 25, higher scores indicating better erectile function)
Change in ejaculatory function
Assessed with MSHQ-EjD short form questionnaire (male sexual health questionnaire - ejaculatory dysfunction short form: score between 1 and 15, higher scores indicating better ejaculatory function)
Change in LUTS
Assessed with Peeling's voiding picture (score between 1 and 4, lower scores indicating better strength of the urinary stream)
Change in LUTS
Assessed with ICIQ-MLUTS module (international consultation on incontinence questionnaire - male lower urinary tract symptoms: score between 0 and 24, higher scores indicating more LUTS)
Change in urinary continence
Assessed with ICIQ-UI short form questionnaire (international consultation on incontinence questionnaire - urinary incontinence: score between 0 and 21, higher scores indicating more urinary incontinence)
Change in maximum flow rate
Assessed with uroflowmetry (Qmax)
Change in quality of life
Assessed with EQ-5D-3L (5 questions on quality of life resulting in digit score, e.g. 11231, higher scores indicating worse quality of life)
Change in quality of life
Assessed with EQ-VAS (EQ-visual analogue scale: scale between 0 and 100, higher scores indicating better quality of life)
Patient satisfaction
Assessed with two general patient satisfaction questions
Postoperative complication rate
Categorized according to the Clavien-Dindo classification system

Full Information

First Posted
June 29, 2020
Last Updated
January 25, 2023
Sponsor
University Hospital, Ghent
search

1. Study Identification

Unique Protocol Identification Number
NCT04551417
Brief Title
DoVe Trial: Dorsal Onlay Versus Ventral Onlay in Isolated Bulbar Urethral Strictures
Acronym
DoVe
Official Title
DoVe Trial: a Randomized Controlled Trial Comparing Dorsal Onlay Versus Ventral Onlay in Isolated Bulbar Urethral Strictures
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 4, 2020 (Actual)
Primary Completion Date
January 1, 2026 (Anticipated)
Study Completion Date
January 1, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Ghent

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
For bulbar urethral strictures, it remains unclear whether ventral onlay graft urethroplasty is non-inferior to dorsal onlay graft urethroplasty in terms of patency rates.
Detailed Description
Urethral stricture disease is a common urological condition in men. Although rigorous epidemiologic data is sparse, the existing papers report an incidence varying between 0.6 and 1.4 percent1. Urethral strictures can occur throughout the entire length of the urethra, but mainly involve the anterior urethra and, in particular, the bulbar segment2. The International Consultation on Urologic Diseases (ICUD) recommends anastomotic repair (AR) urethroplasty for isolated, short, bulbar urethral strictures3. However, AR urethroplasty is only possible up to a certain point of stricture length. The elasticity of the bulbar urethra is estimated to be about 25% and given the average bulbar urethral length of 10 cm, one could simply calculate that strictures up to 2.5 cm can be treated with AR urethroplasty. However, this border of 2.5 cm is rather arbitrary as additional length may be gained through the different maneuvers of Webster et al., enabling the option of AR for even longer strictures4. Furthermore, the location of the stricture within the bulbar segment plays an important role as well: a proximal bulbar stricture location allows AR for longer strictured segments (> 2.5 cm) than a more distal stricture location which nears the penoscrotal angle. Anyhow, the key for a successful AR procedure is to perform a well-vascularized and tension-free anastomosis5. Whenever this is impossible to achieve, even after performing the length-gaining maneuvers of Webster et al., it is recommended to perform a so-called 'substitution urethroplasty' in which the strictured area of the urethra is opened and augmented with a free graft or a pedicled flap5. Within the option of substitution urethroplasty, free graft urethroplasty (FGU) definitely represents the easiest and most straightforward treatment option. Herein, urethral surgeons initially started by placing grafts ventrally 'on' the urethra: 'ventral onlay FGU'. Later, Barbagli et al. started placing grafts dorsally: 'dorsal onlay FGU'6. They advocated that this dorsal graft position would lead to better graft anchorage, less graft mobility and less graft sacculation. However, to date, there is no indisputable data to support the choice of one technique over another, not from a surgical point of view, nor from a functional point of view7. Furthermore, studies investigating this issue are mostly retrospective and thus only entail a low level of evidence7. Against this background, the aim of the DoVe trial is to directly compare dorsal onlay and ventral onlay FGU for both surgical and functional outcome.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Urethra Stenosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
240 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Dorsal onlay graft urethroplasty
Arm Type
Active Comparator
Arm Title
Ventral onlay graft urethroplasty
Arm Type
Experimental
Intervention Type
Procedure
Intervention Name(s)
Free graft urethroplasty
Intervention Description
Free graft urethroplasty will be performed either with ventral or dorsal onlay of the graft.
Primary Outcome Measure Information:
Title
Failure-free survival after 24 months
Description
Failure is defined as the inability to pass a flexible 16 Fr cystoscope through the reconstructed area without damaging the urethral mucosa.
Time Frame
24 months
Secondary Outcome Measure Information:
Title
Change in postoperative erectile function
Description
Assessed with IIEF 5 questionnaire (international index on erectile function: score between 5 and 25, higher scores indicating better erectile function)
Time Frame
Baseline questionnaire, followed by questionnaire at 3, 12 and 24 months of follow-up.
Title
Change in ejaculatory function
Description
Assessed with MSHQ-EjD short form questionnaire (male sexual health questionnaire - ejaculatory dysfunction short form: score between 1 and 15, higher scores indicating better ejaculatory function)
Time Frame
Baseline questionnaire, followed by questionnaire at 3, 12 and 24 months of follow-up.
Title
Change in LUTS
Description
Assessed with Peeling's voiding picture (score between 1 and 4, lower scores indicating better strength of the urinary stream)
Time Frame
Baseline question, followed by question at 3, 12 and 24 months of follow-up.
Title
Change in LUTS
Description
Assessed with ICIQ-MLUTS module (international consultation on incontinence questionnaire - male lower urinary tract symptoms: score between 0 and 24, higher scores indicating more LUTS)
Time Frame
Baseline questionnaire, followed by questionnaire at 3, 12 and 24 months of follow-up.
Title
Change in urinary continence
Description
Assessed with ICIQ-UI short form questionnaire (international consultation on incontinence questionnaire - urinary incontinence: score between 0 and 21, higher scores indicating more urinary incontinence)
Time Frame
Baseline questionnaire, followed by questionnaire at 3, 12 and 24 months of follow-up.
Title
Change in maximum flow rate
Description
Assessed with uroflowmetry (Qmax)
Time Frame
Uroflowmetry at baseline, followed by uroflowmetry at 3, 12 and 24 months of follow-up.
Title
Change in quality of life
Description
Assessed with EQ-5D-3L (5 questions on quality of life resulting in digit score, e.g. 11231, higher scores indicating worse quality of life)
Time Frame
Baseline questionnaire, followed by questionnaire at 3, 12 and 24 months of follow-up.
Title
Change in quality of life
Description
Assessed with EQ-VAS (EQ-visual analogue scale: scale between 0 and 100, higher scores indicating better quality of life)
Time Frame
Baseline questionnaire, followed by questionnaire at 3, 12 and 24 months of follow-up.
Title
Patient satisfaction
Description
Assessed with two general patient satisfaction questions
Time Frame
Assessed after 3, 12 and 24 months of follow-up.
Title
Postoperative complication rate
Description
Categorized according to the Clavien-Dindo classification system
Time Frame
Within 90 days postoperatively

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Voluntarily signed written informed consent according to the rules of Good Clinical Practice (Declaration of Helsinki) and national regulations (Appendix B). Age ≥ 18 years. Male patient. Fit for operation, based on the surgeon's expert opinion. Isolated bulbar urethral stricture confirmed by imaging. Preputium, penile shaft skin, buccal mucosa and lingual mucosa are allowed as free graft material in the executed dorsal onlay or ventral onlay FGU. Patient is able and willing to attend the follow-up consultations. Exclusion Criteria: Absence of signed written informed consent (Appendix B). Age < 18 years. Female patients. Transgender patients. Patients unfit for operation. Concomitant urethral strictures at other urethral locations (penile urethra, membranous urethra, prostatic urethra, bladder neck). A unique urethral stricture at other urethral locations (penile urethra, membranous urethra, prostatic urethra, bladder neck). Prior bulbar urethroplasty. Lichen Sclerosus related strictures. Strictures after failed hypospadias repair. Patients with neurogenic bladder. History of pelvic radiation therapy. Shift of technique to any other technique than dorsal or ventral onlay FGU due to any circumstance (post-hoc exclusion). Utilization of free graft material other than preputium, penile shaft skin, buccal mucosa or lingual mucosa. Any condition or situation, which, in the investigator's opinion, puts the patient at significant risk, could confound the study results, or may interfere significantly with the patient's participation in the study. Patient declares that it will be impossible for him to attend the follow-up consultations.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nicolaas Lumen
Phone
+32 9 332 22 76
Email
nicolaas.lumen@uzgent.be
First Name & Middle Initial & Last Name or Official Title & Degree
Wesley Verla
Phone
+32 9 332 22 76
Email
nicolaas.lumen@uzgent.be
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Nicolaas Lumen
Organizational Affiliation
University Hospital, Ghent
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Wesley Verla
Organizational Affiliation
University Hospital, Ghent
Official's Role
Study Director
Facility Information:
Facility Name
Ghent University Hospital
City
Ghent
ZIP/Postal Code
9000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Wesley Verla
Phone
+32 9 332 22 76
Email
wesley.verla@uzgent.be
First Name & Middle Initial & Last Name & Degree
Nicolaas Lumen
Phone
+32 9 332 22 76
Email
nicolaas.lumen@uzgent.be

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

DoVe Trial: Dorsal Onlay Versus Ventral Onlay in Isolated Bulbar Urethral Strictures

We'll reach out to this number within 24 hrs